stdClass Object
(
    [id] => 10147
    [paper_index] => 202302-02-012495
    [title] => A COMPREHENSIVE REVIEW ARTICLE ON FINERENONE 
    [description] => 
    [author] => Dr.Sanjay Prajapati, Dr. Pratik Prajapati, Kajal Gondaliya
    [googlescholar] => https://scholar.google.co.in/scholar?cluster=8282749593449906904&hl=en&as_sdt=0,5
    [doi] => 
    [year] => 2023
    [month] => February
    [volume] => 8
    [issue] => 2
    [file] => 416pm_36.EPRA JOURNALS 12495.pdf
    [abstract] => Finerenone is a Novel selective Non-steroidal Mineralocorticoids  Receptor Antagonist. Finerenone is  indicated for the treatment of Chronic kidney disease (stage 3 and stage 4) associated with type 2 diabetes in adults. Finerenone blocks the MR receptor so that the progression of chronic kidney disease is control. Finerenone belongs to the BCS class-II, low solubility and low half life and bioavailbility.
    [keywords] => Finerenone, Chronic kidney disease, Solubility, BCS Class.
    [doj] => 2023-02-25
    [hit] => 2445
    [status] => y
    [award_status] => P
    [orderr] => 36
    [journal_id] => 2
    [googlesearch_link] => https://www.google.com/search?q=A+COMPREHENSIVE+REVIEW+ARTICLE+ON+FINERENONE+Dr.Sanjay+Prajapati%2C+Dr.+Pratik+Prajapati%2C+Kajal+Gondaliya&rlz=1C1CHBD_enIN959IN959&sourceid=chrome&ie=UTF-8
    [edit_on] => 
    [is_status] => 1
    [journalname] => EPRA International Journal of Research & Development (IJRD)
    [short_code] => IJSR
    [eissn] =>  2455-7838 (Online)
    [pissn] => - -
    [home_page_wrapper] => images/products_image/2-n.png
)
Error fetching PDF file.